Evidence map›Paper›PMID 39968190›Full record

ArticleThe Lancet regional health. Europe2025

Eligibility criteria for lung cancer screening in France: a modelling study.

Xiaoshuang Feng, Karine Alcala, Florence Guida, Marcel Goldberg, Marie Zins, Olivier Leleu, Pianpian Cao, Jihyoun Jeon, Sébastien Couraud, Mattias Johansson and 1 more

Abstract read
In one paragraph

Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaoshuang FengGenomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Karine AlcalaGenomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Florence GuidaEnvironment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Marcel GoldbergUniversité Paris Cité, "Population-based Cohorts Unit", INSERM, Paris Saclay University, UVSQ, UMS 011, Paris, France.
Marie ZinsUniversité Paris Cité, "Population-based Cohorts Unit", INSERM, Paris Saclay University, UVSQ, UMS 011, Paris, France.
Olivier LeleuDepartment of Pulmonology, Centre Hospitalier d'Abbeville, Abbeville, France.
Pianpian CaoDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jihyoun JeonDepartment of Epidemiology, University of Michigan, Ann Arbor, MI, United States.
Sébastien CouraudService de Pneumologie et Oncologie Thoracique, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France.
Mattias JohanssonGenomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Hilary A RobbinsGenomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background: We estimated the potential impact of different eligibility criteria for lung cancer screening in France, to inform a planned national pilot program. Methods: We simulated the French population by integrating national population estimates and smoking prevalence with lung cancer risk factors from the CONSTANCES cohort. We predicted lung cancer cases and deaths using the Lung Cancer [Death] Risk Assessment Tool for individuals with a smoking history. We evaluated four screening eligibility strategies: the US Preventive Services Task Force criteria (USPSTF) 2013, USPSTF-2021, NELSON, and a risk-based strategy (PLCOm2012 model). Findings: We simulated 14,860,000 individuals with a smoking history aged 50-80 years in France. We estimated 11,000-14,000 preventable lung cancer deaths over 5 years by screening 2.4-4.0 million individuals, depending on eligibility criteria. When screening the same number of individuals, we estimated the risk-based strategy would identify an additional 12-22% preventable lung cancer deaths compared with categorical criteria. Individuals selected by risk-based criteria were typically 5-7 years older, with 4-6 years shorter life expectancy, but categorical criteria selected many individuals with low anticipated screening benefit (33% among USPSTF-2021-eligible). Restricting to individuals aged 50-74, 55-80, and 55-74 years gave smaller differences between categorical and risk-based criteria in age (2-6 years difference), life expectancy (2-5 years difference), and preventable lung cancer deaths (6-17% difference). Interpretation: Screening high-risk individuals for lung cancer might prevent over 10,000 lung cancer deaths in France over 5 years, with potentially higher efficiency for risk-based eligibility compared with categorical criteria. Funding: l'Institut National du Cancer.

Indexed as

EligibilityLung cancerRisk-based strategyScreening

Identifiers

PMID39968190
PMCPMC11833608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.